Mounjaro for prediabetes: the off-label progression-prevention case

TLDR. Tirzepatide reduced the risk of progression to type 2 diabetes by 94 percent at 176 weeks in the SURMOUNT-1 prediabetes subgroup. The published result is one of the largest progression-prevention effects in metabolic medicine. Mounjaro is FDA-approved for type 2 diabetes, not prediabetes. Patients seeking treatment under a prediabetes diagnosis pay cash, around $1,069 per month at retail or $349 to $499 monthly through LillyDirect vials. The metformin alternative remains far cheaper and still works.

The clinical pattern that makes prediabetes hard: roughly 38 percent of US adults meet the laboratory threshold (A1C 5.7 to 6.4, or impaired fasting glucose, or impaired glucose tolerance), but only about 19 percent know they have it. Of those who know, the majority do not act. Of those who do act, the standard interventions (metformin, structured lifestyle, weight loss) prevent progression in roughly 30 to 60 percent of cases. The remaining patients progress to T2D within 3 to 10 years.

Tirzepatide enters that picture with a result that, on the face of it, looks too large to ignore.

What SURMOUNT-1 actually showed in the prediabetes arm

SURMOUNT-1 was the phase 3 trial of tirzepatide for obesity, enrolling 2,539 adults with BMI 30 or higher (or 27 with comorbidity), randomized to tirzepatide 5 mg, 10 mg, 15 mg weekly, or placebo. The headline result at 72 weeks: 15 to 21 percent body weight reduction on tirzepatide versus 3 percent on placebo.

The trial then ran an extension study, SURMOUNT-1 prediabetes follow-up, in 1,032 participants with prediabetes at baseline. At 176 weeks (treatment plus follow-up), the prediabetes-to-T2D progression rate was 1.3 percent on tirzepatide pooled doses versus 13.3 percent on placebo. Hazard ratio 0.07, 95 percent CI 0.04 to 0.10. That is a 94 percent relative-risk reduction. Weight regain after stopping tirzepatide reversed roughly half of the benefit by 17 weeks post-discontinuation, suggesting the effect requires ongoing treatment.

For context, the Diabetes Prevention Program (DPP) showed a 58 percent risk reduction with intensive lifestyle and 31 percent with metformin over 3 years. The SURMOUNT-1 tirzepatide effect is much larger but at substantially higher cost and on a different evidence quality (a single trial of one molecule, versus DPP's 27-site, 3,234-patient gold-standard design).

Why there is no prediabetes indication

FDA approval requires a specific indication tied to an efficacy and safety dataset. Eli Lilly has not submitted a prediabetes-specific indication for Mounjaro. The likely reasons:

• The progression-prevention finding came from a subgroup analysis of an obesity trial, not a primary-endpoint trial for progression specifically.
• Submitting a prediabetes indication would require additional trials and potentially a long-term cardiovascular safety dataset to support broad use in a low-risk population.
• Off-label use already routes through obesity-indication coverage where insurance is willing.
• The commercial incentive to file is weaker than it looks: prediabetes patients can already access Mounjaro or Zepbound through the obesity pathway if they have BMI 27 plus a qualifying comorbidity.

The practical effect: prediabetes is not a covered indication, will not be on the label, and is unlikely to appear on the label within the next 2 to 3 years.

The off-label paths that do work

Prediabetes patients access tirzepatide through three routes in 2026:

1. Zepbound under obesity. If BMI is 30 or higher, or 27 plus comorbidity, the standard obesity PA path applies. Prediabetes counts as a comorbidity for the BMI 27 threshold. This is the cleanest route. Insurance copays land at $25 to $150 per month with PA approved.
2. Mounjaro under T2D, off-label. A few patients still get Mounjaro prescribed off-label for prediabetes when their A1C is close to but below the T2D threshold (6.5). PA outcomes are inconsistent and often rejected. Not a reliable path.
3. Cash-pay through LillyDirect. Zepbound vials at $349 to $499 per month is the cleanest cash-pay path. Mounjaro pens cash-pay are about $1,069 per month retail; that is not a route most patients pursue.

The metformin question

Metformin remains the standard off-label intervention for prediabetes. Cost: $4 to $15 per month. Evidence base: decades of safety and efficacy data, plus the DPP and DPPOS long-term follow-up. The mean weight loss in DPP was about 2 percent. The progression reduction was 31 percent at 3 years.

If you compare metformin to tirzepatide directly:

• Metformin progression reduction: 31 percent (DPP)
• Tirzepatide progression reduction: 94 percent (SURMOUNT-1 prediabetes subgroup)
• Metformin monthly cost: $4 to $15
• Tirzepatide monthly cost: $349 to $1,069 cash, or $25 to $150 with insurance
• Metformin GI side effects: 20 to 30 percent of patients in the first 4 to 6 weeks
• Tirzepatide GI side effects: 30 to 40 percent of patients during titration

The reasonable starting point for most prediabetes patients remains metformin plus structured lifestyle. If A1C does not improve at 6 months and the BMI threshold qualifies for the obesity pathway, adding or switching to tirzepatide is reasonable. Combination metformin plus tirzepatide is increasingly common in 2026 practice.

The cost-effectiveness math

For a 50-year-old patient with prediabetes and BMI 32:

• Untreated 5-year progression risk to T2D: roughly 25 to 35 percent.
• On metformin: 17 to 24 percent.
• On tirzepatide (extrapolating from SURMOUNT-1): 2 to 5 percent.
• Cost of 5 years of tirzepatide cash-pay (vials, LillyDirect): roughly $21,000 to $30,000.
• Cost of 5 years of T2D care if progression occurs: roughly $7,000 to $15,000 (modest insurance burden).

Pure cost-prevention math comes out unfavorable for the cash-pay tirzepatide patient. The math improves when you factor in weight loss, cardiometabolic risk reduction beyond T2D, and quality-of-life endpoints. The math improves dramatically when insurance covers the medication.

The honest patient case

For a patient with prediabetes (A1C 5.9, BMI 32) and a strong family history of T2D:

• If you have BMI 30 or higher, you qualify for the obesity PA pathway. Pursue Zepbound under obesity, not Mounjaro under prediabetes.
• If your BMI is 27 to 29, you still qualify under BMI 27 plus comorbidity if any comorbidity exists. Prediabetes itself, hypertension, dyslipidemia, OSA, and PCOS all count.
• If your BMI is below 27 and your only qualifying condition is prediabetes, you have no insurance route. Cash-pay or metformin are the options.
• Metformin alone is still appropriate first-line for many patients. It is not a wrong answer, even with the SURMOUNT-1 numbers on the table.

The cohort that benefits most from tirzepatide in prediabetes

Not all prediabetes patients should pursue tirzepatide even if cost were no object. The cohort with the strongest case:

• A1C trending upward over multiple measurements despite metformin and lifestyle.
• BMI 30 or higher, qualifying for the obesity-indication PA route.
• Strong family history of T2D and CV disease.
• Personal history of gestational diabetes or PCOS (markers of latent insulin-resistance trajectory).
• Visceral adiposity disproportionate to BMI, with elevated waist circumference and high fasting insulin.
• Patient motivation for long-term treatment, recognizing the discontinuation-relapse pattern.

The cohort with the weakest case is the opposite: stable A1C in the low prediabetes range, BMI under 27, no comorbidities, and a short personal time horizon. For these patients, metformin plus lifestyle is the right starting answer.

The diabetes-prevention math at population scale

From a public-health perspective, the prediabetes-to-T2D progression-prevention question is one of the highest-impact interventions in metabolic medicine. Estimates:

• 96 million US adults have prediabetes per CDC 2024 data.
• Without intervention, roughly 5 to 10 percent progress to T2D each year, with cumulative 5-year progression around 25 to 35 percent.
• If tirzepatide reduced progression by 50 to 80 percent in a real-world cohort (more conservative than the 94 percent trial estimate), the absolute impact on the T2D incidence curve would be substantial.
• The cost-effectiveness calculation depends heavily on durability of effect, drug price, and selection of higher-risk patients.

The realistic 2026 picture: cost-prohibitive at scale, viable for selected high-risk individuals with comorbidity-driven coverage paths. Generic semaglutide arrival in late 2026 to early 2027 will likely shift the calculus toward broader population use within 18 to 24 months.

Combining tirzepatide with structured lifestyle intervention

The DPP showed intensive lifestyle was 58 percent effective at 3 years. SURMOUNT-1 prediabetes was 94 percent effective at 176 weeks. Combined intervention has not been formally trialed, but the DPP design is well-validated and overlapping with tirzepatide rather than competing.

The pattern many obesity-medicine clinics use:

• Start tirzepatide for the pharmacologic effect.
• Refer to a registered dietitian or evidence-based lifestyle program (DPP-modeled, YMCA Diabetes Prevention Program, or telehealth-based equivalent).
• Set protein and resistance-training targets to preserve lean mass during weight loss.
• Monitor at 12-week intervals during titration, then quarterly through year 1.

The combination is more durable than either alone, particularly when patients eventually discontinue or reduce tirzepatide. Patients who built lifestyle habits during the weight-loss phase retain more weight after stopping medication.

Frequently asked questions

Can I get Mounjaro under a prediabetes diagnosis?

Not reliably. Mounjaro is approved for type 2 diabetes, defined as A1C 6.5 or higher (or other diagnostic criteria). Prescribing under an A1C of 5.7 to 6.4 is off-label, and PA approvals at that level are inconsistent. The cleaner route for a prediabetes patient with BMI 27 or higher is Zepbound under the obesity indication.

Is the 94 percent risk reduction real?

The number comes from a subgroup analysis of SURMOUNT-1 with 176 weeks of follow-up. It is statistically solid within the trial but represents one trial of one molecule. The effect size is also partly explained by the magnitude of weight loss. Replication in dedicated prediabetes trials would strengthen the inference. Realistic expectation: the effect is large, but maybe 50 to 80 percent in less-selected real-world populations rather than the 94 percent from the trial.

What if I stop tirzepatide after my prediabetes resolves?

The trial extension showed about half of the benefit reversed within 17 weeks of discontinuation, with weight regain mirroring the STEP-4 semaglutide-discontinuation pattern. Sustained protection appears to require sustained treatment. This is the same pattern that applies to most cardiometabolic drugs.

Should I get an oral glucose tolerance test?

For prediabetes confirmation, A1C plus fasting glucose is usually sufficient. An OGTT adds sensitivity (catches impaired glucose tolerance that A1C and fasting miss) and is sometimes ordered when A1C is borderline. Most patients do not need an OGTT.

Does metformin still help if I am on tirzepatide?

Combination metformin plus tirzepatide is used in T2D and PCOS practice. The clinical evidence for combination in prediabetes specifically is thin, but the mechanisms are complementary. Many obesity-medicine clinicians start metformin during a tirzepatide pause or as primary therapy in patients who cannot afford ongoing tirzepatide.

For the broader Mounjaro drug profile, see Mounjaro. For the closely related metabolic-syndrome condition, see PCOS with metabolic syndrome. For the head-to-head tirzepatide-semaglutide comparison, see tirzepatide versus semaglutide direct comparison. For metformin and cheaper alternative comparison, see GLP-1 versus cheap alternatives honestly. For the obesity-with-comorbidity PA letter, see obesity with comorbidity PA letter.

Citations

• Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022;387:205-216. nejm.org/doi/full/10.1056/NEJMoa2206038
• Garvey WT, et al. Tirzepatide and prevention of type 2 diabetes in obesity (SURMOUNT-1 prediabetes follow-up). NEJM 2024 (online ahead of print). nejm.org/doi/full/10.1056/NEJMoa2410819
• Knowler WC, et al. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin (DPP). NEJM 2002;346:393-403. nejm.org/doi/full/10.1056/NEJMoa012512
• Mounjaro prescribing information, Eli Lilly, current label. accessdata.fda.gov/drugsatfda_docs/label/2024/215866s007lbl.pdf
• ADA Standards of Care in Diabetes 2024, section 3: Prevention or delay of type 2 diabetes. Diabetes Care 2024;47(Suppl 1):S43-S51. diabetesjournals.org/care/issue/47/Supplement_1